Nephros (NEPH) Gross Margin (2010 - 2026)

Nephros' Gross Margin history runs 17 years deep, the most recent figure standing at 57.43% for Q1 2026.

• On a quarterly basis, Gross Margin fell 725.0% year-over-year to 57.43% in Q1 2026; TTM through Mar 2026 was 59.95%, a 250.0% decrease from a year earlier, with the FY2025 full-year figure at 61.87%, up 28.0% from the prior year.
• Gross Margin declined to 57.43% in Q1 2026 per NEPH's latest filing, from 58.38% in the prior quarter.
• Across five years, Gross Margin topped out at 64.67% in Q1 2025 and bottomed at 31.63% in Q3 2022.
• The 5-year median for Gross Margin is 58.79% (2024), against an average of 57.39%.
• Biggest YoY gain for Gross Margin was 2961 bps in 2022; the steepest drop was 923 bps in 2022.
• Year by year, Gross Margin stood at 58.99% in 2022, then rose by 5 bps to 62.11% in 2023, then increased by 3 bps to 63.95% in 2024, then retreated by 9 bps to 58.38% in 2025, then decreased by 2 bps to 57.43% in 2026.
• Per Business Quant, the three latest NEPH Gross Margin figures stand at 57.43% (Q1 2026), 58.38% (Q4 2025), and 61.19% (Q3 2025).